GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » Price-to-Free-Cash-Flow

Spark Therapeutics (Spark Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-26), Spark Therapeutics's share price is $113.57. Spark Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.71. Hence, Spark Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Spark Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

ONCE's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Spark Therapeutics's Free Cash Flow per Share for the three months ended in Sep. 2019 was $-0.67. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-4.71.


Spark Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Spark Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spark Therapeutics Price-to-Free-Cash-Flow Chart

Spark Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Spark Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Spark Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Spark Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spark Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spark Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Spark Therapeutics's Price-to-Free-Cash-Flow falls into.



Spark Therapeutics Price-to-Free-Cash-Flow Calculation

Spark Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=113.57/-4.71
=N/A

Spark Therapeutics's Share Price of today is $113.57.
Spark Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.71.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Spark Therapeutics  (NAS:ONCE) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Spark Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Spark Therapeutics (Spark Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104
Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.
Executives
Elliot Sigal director
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster officer: CHIEF FINANCIAL OFFICER C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga officer: Chief Business Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth director, officer: CHIEF SCIENTIFIC OFFICER 334 CR 692, BUFFALO GAP TX 79508
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High director, officer: See Remarks 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey officer: Chief Operating Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio officer: Chief Commercial Officer 225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju 10 percent owner 565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

Spark Therapeutics (Spark Therapeutics) Headlines

From GuruFocus